Blockade of epidermal growth factor receptor (EGFR) has been proved useful in enhancing the effect of radiotherapy, but the advantages of new generation EGFR tyrosine kinase inhibitors in radiosensitization are not well known. We used two human bladder cancer cells with wild-type EGFR and HER2 to study the synergism between irradiation and afatinib (an EGFR/HER2 dual kinase inhibitor) or erlotinib (an EGFR kinase inhibitor). Here, we showed that afatinib has better radiosensitizing effect than erlotinib in increasing cancer cell killing, percentage of apoptotic cells and DNA damage. Afatinib is also superior to erlotinib in combining radiation to decrease tumor size, inhibit glucose metabolism, and enhance apoptotic proteins in vivo. Finally, erlotinib suppressed cell growth and induced more DNA damage in bladder cancer cells transfected with HER2 shRNA but not in control vector-treated cells. In conclusion, concomitant blockade of radiation-activated EGFR and HER2 signaling by a new generation EGFR tyrosine kinase inhibitor better inhibits the growth of bladder cancer cells both in vitro and in vivo. The absence of radiosensitization by EGFR or HER2 inhibition alone and the greater radiosensitizing effect of EGFR inhibitor in HER2 knocked-down cells suggests the synergism between HER2 and EGFR in determining radiosensitivity. The regained radiosensitizing activity of erlotinib implies that with proper HER2 inhibition, EGFR tyrosine kinase is still a potential target to enhance radiotherapy effect in these seemingly unresponsive bladder cancer cells.
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instructions. The immunoprecipitates (50 μg) of cells were eluted, resolved by 8% SDS-PAGE, electrotransferred to PVDF membranes and incubated with primary antibodies.
For whole-cell preparations, tumor tissue from individual animals was homogenized with a motor driven pestle and then lysed in 0.2 ml of RIPA lysis buffer/20 mg tissue. The homogenate was then centrifuged (13,000 g) for 10 min and the supernatant was used as whole-cell extract. Bound antibodies were detected using appropriate peroxidase-coupled secondary antibodies followed by enhanced electrochemiluminescence (Roche Diagnostics; Basel, Switzerland). The antibodies used were EGFR, HER2, phosphor-Akt (Ser473), caspase-3, cleaved caspase-3, poly(ADP-ribose) polymerase (PARP), cleaved PARP (Cell Signaling Technology), phospho-EGFR (pY1086), phospho-HER2 (pY1139) (Epitomics, Burlingame, CA), and beta-actin (Santa Cruz Biotechnology, Santa Cruz, CA).
Chemical cross-linking
Samples for the cross-linking analysis were obtained at 60 minutes after various treatments.
The cells were washed with phosphate buffered saline (PBS) three times and incubated for 60 min at room temperature with 5 mM Suberic acid bis(3-sulfo-N-hydroxysuccinimide ester) sodium salt (Sigma-Aldrich) in PBS, and the reaction was terminated using 20mM Tris-HCl, pH 8.5 for 15 min at room temperature. Subsequently, cells were washed with PBS and solubilized in lysis buffer. The collected proteins were subjected to western blotting using 
HER2 RNA interference and stable transfection
To knockdown HER2 gene expression, we used a target-specific lentiviral vector plasmid encoding a 19-25 nt hairpin shRNA (Santa Cruz Biotechnology, cat. no. sc-29405-SH). One day before transfection, T24 and NTUB1 bladder cancer cells were seeded into 6-well culture plates and grown until 70-90% confluent for transfection. A mixture of HER2 shRNA plasmid or scramble plasmid (Santa Cruz Biotechnology, cat. no. sc-108083), blank Dulbecco's modified Eagle's medium, and lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA) at a ratio of 1 μg:98 μl:2 μl was added to the T24 and NTUB1 cells, according to the manufacturer's instructions. The cells were incubated 5-7 h at 37C, harvested, and incubated with 2 μg/ml puromycin (Invitrogen) to select stable clones. The efficiency of HER2 knockdown in T24 and NTUB1 cells was confirmed by Western blot.
Mouse xenograft models
Male athymic ICR nude mice (6-to 8-weeks old; BioLASCO, Ilan, Taiwan) were housed in sterilized cages under 12 h light/dark cycles and given ad libitum access to food and water. Tsai et al. 13
Statistical analysis
The paired-comparisons were assessed using the Student t test. Differences were considered significant at p< 0.05. 
Results

Concomitant EGFR and HER2 tyrosine kinase inhibition significantly suppresses radiation-activated signaling pathways
To understand the impact of irradiation on the phosphorylation of receptor tyrosine kinases (RTK) and key signaling proteins, we used an RTK signaling antibody array to determine the change in intensity of phosphorylated proteins 24 hours after irradiation in T24 bladder cancer cells. Figure 1A and 1B demonstrates that phosphorylation of EGFR, HER2, and downstream signals were enhanced after irradiation of these bladder cancer cells. Treatment with 100 nM afatinib 30 min before irradiation significantly suppressed the level of phosphorylated EGFR, HER2, Akt (Thr308 and Ser473), mitogen-activated protein kinases (MAPK), and S6 ribosomal proteins. In contrast, 100 nM erlotinib pretreatment followed by irradiation suppressed only levels of phospho-EGFR and phospho-MAPK. These results showed that afatinib (a tyrosine kinase inhibitor with activity against EGFR and HER2) inhibits radiation-activated signaling pathways and is a more efficient suppressor than erlotinib (a tyrosine kinase inhibitor blocking EGFR activity) in blocking the phosphorylation of HER2, Akt, and S6 ribosomal protein. The clonogenic assays of T24 and NTUB1 bladder cancer cells after treatment with afatinib or erlotinib once a day for three consecutive days and irradiation on the first day demonstrated that afatinib dose-dependently decreased the clonogenic survival of both cells ( Fig. 2A and 2B ) whereas erlotinib had no such effect, even at 1500 nM ( Fig. 2C and 2D ).
The result indicated that EGFR/HER2 dual inhibitor (compared with EGFR inhibitor) was a better radiosensitizing agent of bladder cancer cells.
Combined EGFR and HER2 tyrosine kinase inhibition promotes radiation-induced apoptosis
To understand whether drug-mediated enhancement of radiosensitivity was due to synchronization of the cell cycle, propidium iodide staining and flow cytometry were used to determine the cell cycle phase distribution of bladder cancer cells 24 hours after the treatment.
As shown in Figure 3A 
Effects of combining irradiation and afatinib on cell apoptosis
We subsequently assessed the expression of apoptosis markers, cleaved forms of caspase 3 and PARP, in the two bladder cancer cell lines 24 hours after treatment. As shown in Fig. 3E , afatinib pretreatment combined with irradiation (when compared with irradiation or afatinib treatment alone) resulted in greater expression of cleaved forms of caspase-3 and PARP in both NTUB1 and T24 cells. The result further validates the finding that afatinib increases radiation-induced cell apoptosis. 
Combined EGFR and HER2 tyrosine kinase inhibition enhances radiation-induced
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DNA damage
Since radiation-induced DNA damage is a common cause leading to cancer cell apoptosis, we investigated whether tyrosine kinase inhibition by afatinib or erlotinib modulates the level of unrepaired DNA damage. We assessed the quantity of phosphorylated histone H2AX (γ-H2AX), which forms foci at DNA double-strand breaks and recruits double-strand break repair proteins. As shown in Fig. 4A to 4D , following 2.5 Gy of radiation, DNA damage in The superior radiosensitizing effect of afatinib over erlotinib is probably through HER2 inhibition Given the in vitro and in vivo superiority of the EGFR/HER2 dual tyrosine kinase inhibitor (afatinib) over the EGFR inhibitor (erlotinib) in radiosensitizing bladder cancer cells, it is reasonable to suggest that HER2 synergizes with EGFR to determine the level of radiosensitivity. To prove this hypothesis, we used a target-specific lentiviral vector plasmid to silence HER2 expression by RNA interference. The expression of HER2 in T24 and NTUB1 bladder cancer cells decreased dramatically after the transfection with this plasmid (Fig. 6A and Supplemental Fig. 2A ). Clonogenic assays showed that pretreatment with different concentrations of erlotinib had a radiosensitizing effect on T24 and NTUB1 cells transfected with HER2 shRNA (Fig. 6B and Supplemental Fig. 2B ) but not on T24 and NTUB1 cells transfected with control vector (Fig. 6C and Supplemental Fig. 2C ). Meanwhile, pretreatment with afatinib in control vector-transfected T24 and NTUB1 cells retained the radiosensitizing effect ( Fig. 6D and Supplemental Fig. 2D ).
The number of γH2AX foci in T24 and NTUB1 cells transfected with HER2 shRNA was higher after treatment with the erlotinib-radiation combination than with radiation alone (Fig. 6E, 6F and Supplemental Fig. 2E, 2F 
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In summary, the radiosensitizing effects of different generations of clinically useful EGFR TKIs were compared for the first time. We show the inadequacy of EGFR inhibition alone and the advantage of concomitant blockade of radiation-activated EGFR and HER2 signaling to inhibit the in vitro and in vivo growth of bladder cancer cells. The radiosensitizing effect of an EGFR inhibitor was much higher in HER2 knocked-down than wild-type cells, therefore HER2 may play a synergistic role with EGFR in determining radiosensitivity. The regained radiosensitizing activity of erlotinib implies that with proper HER2 inhibition, EGFR tyrosine kinase is still a potential target to enhance radiotherapy effect in these seemingly unresponsive bladder cancer cells. 
